Paris – ScreenCell today released a white paper that details a “next generation” technology for fast isolation of undamaged fixed cells and viable live circulating tumor cells

ScreenCell.com Published on January 15th, 2013

ScreenCell offers a white paper on effective circulating tumor cells isolation

 Paris– ScreenCell today released a white paper that details a “next generation” technology for fast isolation of undamaged fixed cells and viable live circulating tumor cells.

The white paper entitled Rapid and Simple isolation of Circulating Tumor Cells for Clinical and Research Applications using ScreenCell (http://www.screencell.com/wp-content/uploads/2013/01/ScreenCell-White-Paper.pdf) highlights the difficulty most systems have of effectively isolating cells and details the advantages brought by the use of non invasive handheld – independent of any equipment – innovating devices.

Most commonly used systems base CTC capture according to their expressed level of certain protein such as EpCam, this approach generates biases and does not allow the isolation of cells not expressing those specific markers as it is the case for certain types of cancer such as melanoma or pancreas, or expressing those markers but only before their epithelial – mezenchymal transition.

Size base cell selection suppresses the bias introduced by antibody based cell capture.

CTCs isolation systems, especially when they can be used as point of care devices – such as ScreenCells’ –  are the only non invasive approach allowing to:

 

  • Understand the mechanisms responsible for disease or tumor progression
  • Monitor the efficacy of targeted therapies and patients’ treatments
  • Allow earlier prediction of metastatic risks

About ScreenCell

ScreenCell was founded with the objective of designing and producing a simple but revolutionary technique allowing the fast and effective isolating of fixed and live Rare Circulating Cells yielding free of any bias CTC population amenable to better cellular and molecular characterization important in cancer monitoring. The technology also contributes to the development of a new non-invasive approach to prenatal diagnosis.

 

Contact:

Michèle Arnoe

VP Business Development

+33 (0)1 53 61 37 96


Need more information? Please Contact us